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A B S T R A C T
Background: Psoriasis vulgaris is characterised by epidermal hyper-proliferation and inﬁltration of
immune cells including dendritic cells (DCs) and T cells. The inﬂammation is driven by a complex
interplay between immune and skin cells involving interleukin (IL)-17A, IL-23 and TNF-a as key drivers.
The calcipotriol/betamethasone dipropionate two-compound ﬁxed combination product is widely used
for topical treatment of psoriasis. However, the mechanism behind its high efﬁcacy has not been
elucidated in detail.
Objective: Here, we investigated and compared the immune modulatory effects of betamethasone,
calcipotriol and the combination in ex vivo cultures of psoriatic skin and in vitro cultures of primary
human cells that recapitulate key cellular activities of psoriatic inﬂammation.
Method: The immune modulatory effect of the treatments on psoriatic skin and on in vitro differentiated
Th1/Th17 cells, Tc1/Tc17 cells, monocyte-derived inﬂammatory dendritic cells and primary keratinocytes
was assessed by a panel of inﬂammatory and phenotypic related transcription factors and cytokines. The
expression was evaluated by both gene and protein analysis.
Results: Compared to vehicle control or mono-treatments, the effect of calcipotriol/betamethasone
combination was signiﬁcantly better in inhibiting the secretion of IL-17A and TNF-a in psoriatic skin.
Additionally, the two components showed additive inhibitory effects on secretion of IL-23 and TNF-a by
DCs, of IL-17A and TNF-a by both CD4+ and CD8+ T cells and reduced inﬂammatory responses in Th17-
stimulated keratinocytes. Furthermore, calcipotriol was found to enhance IL-10 secretion in psoriatic skin
and in human T cells, to induce secretion of type 2 cytokines by T cells and, lastly, to signiﬁcantly
modulate the differentiation of DCs and T cells.
Conclusions: In summary, we demonstrate a unique and supplementary immune modulatory effect of
calcipotriol/betamethasone combination on TNF-a and IL-23/Th17 immune axis, supporting the superior
clinical efﬁcacy of the combination product compared to the respective mono-treatments in psoriasis
patients.
ã 2016 The Authors. Published by Elsevier Ireland Ltd on behalf of Japanese Society for Investigative
Dermatology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Psoriasis is an immune-mediated, chronic inﬂammatory skin
disease clinically characterised by well-deﬁned, raised, red andAbbreviations: ELISA, enzyme-linked immunosorbent assay; VDR, vitamin D
receptor; Tc cell, T cytotoxic cell; Th cell, T helper cell; Treg cell, T regulatory cell;
Tcm, central memory T cells; Tem, effector memory T cells; RORC, RAR-related orphan
receptor C; GATA3, GATA binding protein 3; FOXP3, forkhead box P3.
* Corresponding author at: Department of Skin Inﬂammation Pharmacology, LEO
Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark.
E-mail address: paola.lovato@leo-pharma.com (P. Lovato).
http://dx.doi.org/10.1016/j.jdermsci.2015.12.009
0923-1811/ ã 2016 The Authors. Published by Elsevier Ireland Ltd on behalf of Japanese S
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).scaly plaques that affects approximately 1–3% of the population
worldwide although the prevalence is below 0.5% in Asia [1].
Histologically, psoriasis is characterised by epidermal hyper-
proliferation with disordered keratinocyte differentiation, inﬂam-
matory cell inﬁltration and increased vascularity in the dermis [2].
An immune pathogenesis model of psoriasis involving dendritic
cells (DCs), T cells and keratinocytes (KCs) has now been
established. Activated inﬂammatory DCs produce tumour necrosis
factor-a (TNF-a), interleukin (IL)-12 and IL-23, and these cytokines
maintain or stimulate Th1, Th17 and Th22 cells [3]. Subsequently,
IL-17, interferon-g (IFN-g) and IL-22 secreted from these cellsociety for Investigative Dermatology. This is an open access article under the CC BY-
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additional inﬂammatory mediators such as chemokines, cytokines
and antimicrobial peptides. Inhibition of TNF-a has been known to
be an effective therapy in psoriasis for more than a decade. More
recently, IL-23 and IL-17A are recognised as key cytokines of
psoriasis pathogenesis through the documented clinical efﬁcacy of
antagonists to these cytokines that control disease in approxi-
mately 80% of treated patients with moderate–severe psoriasis [3].
The combination of the vitamin D receptor (VDR) agonist
calcipotriol and betamethasone dipropionate is a ﬁrst-line topical
treatment for mild to moderate plaque psoriasis [4,5]. There are
considerable differences between glucocorticoids and VDR ago-
nists in modulation of the immune system [6–8]. Glucocorticoids
are potent anti-inﬂammatory agents with broad immunosuppres-
sive effects by blocking several inﬂammatory pathways [9,10], and
by inducing apoptosis [11]. In contrast, VDR agonists promote a
more immune modulatory proﬁle by inducing a tolerogenic state
in DCs and T cells [12–14], and by enhancing the immunosuppres-
sive capacity of regulatory T cells [15,16]. Whereas corticosteroids
broadly inhibit T cell activities, VDR agonists drive T cells towards a
Th2 proﬁle while inhibiting Th1/Th17 cells [17]. Studies using
peripheral blood-derived T cells from patients with rheumatoid
arthritis demonstrate decreased production of the Th1/
Th17 cytokines IFN-g and IL-17A and increased production of
the Th2 cytokine IL-4 upon treatment with calcipotriol, which
contrasts the more universal inhibitory effects of dexamethasone
[18]. Calcipotriol also normalises the pro-inﬂammatory cytokine
milieu in psoriasis, including a decrease of IL17A, IL17F and IL8
transcripts in psoriatic skin and inhibition of Th17-induced
expression of IL-6, IL-8, human beta defensin (HBD)-2, -3,
S100A7, and S100A15 in KCs [19–21], thereby interrupting the
pro-inﬂammatory feedback loop that drives the pathogenesis.
In light of the differentiated effects of VDR agonists and
glucocorticoids on inﬂammatory responses and their conﬁrmed
clinical effect on psoriasis, it is relevant to explore the molecular
effects of combining a corticosteroid and a VDR agonist on the key
cell types involved in psoriasis pathogenesis. In this study, we
investigated the effects of calcipotriol, betamethasone dipropio-
nate and their combination on cytokine expression in ex vivo
cultures of psoriatic skin that maintains the key cellular activities
and inﬂammatory features as found in psoriatic skin in vivo in
patients. Furthermore, to delineate the effects of the agents on
speciﬁc cell types of central importance in psoriasis, studies were
performed using in vitro cultures of primary human KCs, DCs and T
cells, differentiated into subsets of relevance to psoriasis.
2. Materials and methods
2.1. Test compounds
Stock solutions (10 mM) of calcipotriol (MC 00903; LEO
Pharma) and betamethasone dipropionate (provided by LEO
Pharma) were prepared in dimethyl sulfoxide (DMSO). The stock
solutions were diluted in cell culture medium at the time of use.
The ﬁnal concentration of the compounds was 100 nM of
calcipotriol and 1 mM of betamethasone dipropionate both for
single treatments and for the combination. The ﬁnal concen-
trations of calcipotriol and betamethasone dipropionate used in
this study are based on exposure data in ex vivo pig and human skin
after topical application of the calcipotriol/betamethasone ﬁxed-
combination product.
2.2. Human specimens
Keratome biopsies, 500 mm thick, were obtained from non-
treated lesional skin of patients with active plaque psoriasis afterapproval from local ethical committees and the Danish Data
Protection Agency (No 271113-4E, 15-1427/2 and H-2-2013-011)
and upon written informed consent by the patients.
Buffy coats from healthy adult blood donors were obtained
from the Blood Bank of the National University Hospital
Copenhagen after anonymisation of donor identity carried by
the National University Hospital. The use of these buffy coats for
research was approved by the ethical committee, Region H, The
Capital Region of Denmark.
2.3. Psoriasis skin explant cultures
Keratome biospies were kept cold in Dulbecco’s modiﬁed
Eagle medium (DMEM) containing 100 mg/ml gentamicin and
2.5 mg/ml Fungizone (Gibco, Life Technologies, Carlsbad, CA, USA)
and placed in culture within maximum 30 h. Three skin punches
of 5 mm in diameter were taken from different areas of the
keratome biopsy, pooled and cultured in EpiLife medium
supplemented with 0.2 ng/ml human epidermal growth factor,
0.2% bovine pituitary extract, 5 mg/ml bovine insulin, 5 mg/ml
bovine transferrin and gentamicin (all from Life Technologies),
10 ng/ml rhIL-2 (Gibco, Life Technologies, Minneapolis, MN, USA),
400 U/ml penicillin, 400 mg/ml streptomycin (Gibco, Life Tech-
nologies). In situ activation of T cells and inﬂammatory activity was
resumed by stimulation with 1 mg/ml anti-CD3 and anti-
CD28 antibodies (R&D System), and 50 ng/ml rhIL-23 (R&D
System) resulting in a signiﬁcant and reproducible increase of
cytokine expression. The skin cultures were maintained at 37 C in
5% CO2 and stimulated skin cultures were treated with compounds
or vehicle (0.1% DMSO) in triplicate for 24 h (gene expression
analysis) and 72 h (protein analysis). These time points were
selected based on time course studies to ﬁnd the most optimal
experimental conditions.
Supernatants from ex vivo skin cultures were harvested for
protein analysis of IL-22 by ELISA (Human IL-22 Quantikine ELISA
kit; R&D Systems) and of IL-17A (human IL-17A V-PLEX), IL-8
(Human IL-8 (HA) V-PLEX), IL-10 and TNF-a (Custom V-PLEX MSD
for Proinﬂammatory Panel) using the MSD platform (Meso Scale
Diagnostics, Rockville, MD, USA) according to the manufacturer’s
instruction. Skin samples were processed for RNA extraction and
quantitative real time PCR. Independent experiments were
performed using skin samples from six different donors for gene
expression analysis and from ﬁve different donors for the protein
analysis.
2.4. In vitro differentiation and culture of Th1/Th17 and Tc1/Tc17 cells
CD4+ and CD8+ T cells were isolated from buffy coat fractions by
means of negative selection with RosetteSepTM Human CD4+ T Cell
Enrichment Cocktail and RosetteSepTM Human CD8+ T Cell
Enrichment Cocktail (STEMCELL Technologies, Vancouver, Canada)
according to the manufacturer’s instructions. The purity of isolated
T cells routinely exceeded 95%. Puriﬁed CD4+ and CD8+ T cells were
cultured in X-VIVO 15 medium (LONZA, Basel, Switzerland)
containing 2 mM L-glutamine (GlutaMAX, Gibco, Life Technolo-
gies), 10 ng/ml rhIL-2 and 100 mg/ml penicillin/streptomycin
(Gibco, Life Technologies) at a concentration of 1.5 106 cells/ml
and activated with anti-Biotin MACSiBead particles loaded with
anti-CD3 and anti-CD28 antibodies at 1:1 cell/bead ratio following
manufacturer’s instruction (Miltenyi Biotec Norden AB, Lund,
Sweden). To achieve in vitro Th1/Th17 and Tc1/Tc17 differentiation,
the cultures were supplemented with 10 ng/ml rhTGFb (PeproTech
Nordic, Stockholm, Sweden), rhIL-1b (Gibco, Life Technologies),
rhIL-6, 20 ng/ml rhIL-23 and 1 mg/ml anti-IL-4 and anti-IL-
13 antibodies (R&D System) and cultured at 37 C in 5% CO2 for
7 days. The expression level of all the transcription factors and
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ed cultures and was markedly and signiﬁcantly increased in
differentiated cultures.
Cells cultured under Th1/Th17 or Tc1/Tc17 skewing condition
(0.250 ml cell suspension per well of 24 well plate) were treated
with compounds or vehicle (0.1% DMSO) in duplicates either
during the whole period of in vitro differentiation or for 24 h after
6 days of in vitro differentiation. Importantly, 24 h prior to
termination of in vitro cultures, the cells were thoroughly rinsed
from the differentiation cocktail and cultured for the last 24 h in
X-VIVO 15 medium conditioned only with rhIL-2 and treated with
compounds or vehicle as described above.
There was no signiﬁcant difference in cellular viability under
all culture conditions (data not shown). At termination, super-
natants from in vitro T cell cultures were harvested and assessed
for levels of IFN-g, IL-1b, IL-4, IL-5, IL-8, IL-10, IL-13, TNF-a
(Human TH1/TH2 10-Plex Tissue Culture Kit) and IL-17A (human
IL-17A V-PLEX) by using assay kits from Meso Scale Diagnostics
and IL-22 by ELISA (Human IL-22 Quantikine ELISA kit by R&D
Systems).
Th1/Th17 and Tc1/Tc17 cells were processed for RNA extraction
and quantitative real time PCR. Independent studies were
performed using CD4+ and CD8+ T cells from peripheral blood of
six and four different healthy volunteers, respectively.
2.5. DC cultures
CD14+ cells were isolated from buffy coat fractions by means
of negative selection with RosetteSepTM Human Monocyte
Enrichment Cocktail (STEMCELL Technologies) according to the
manufacturer’s instruction. The purity of isolated CD14+ cells
routinely exceeded 95%. CD14+ cells (5 105 cells/well in 12 well
plate) were cultured in RPMI1640 medium (Gibco, Life Technol-
ogies) supplemented with 2 mM L-glutamine (GlutaMAX, Gibco,
Life Technologies), 10% human heat inactivated serum (Blood
Bank, State University Hospital, Copenhagen, Denmark), 100 mg/
ml penicillin/streptomycin (Gibco, Life Technologies) and differ-
entiated to DCs by culturing in the presence of 50 ng/ml rhIL-
4 and 100 ng/ml rhGM-CSF (R&D System) for 5 days at 37 C in
5% CO2. Subsequently, monocyte-derived DCs were fully matu-
rated and activated by co-stimulation with 100 ng/ml lipopoly-
saccharide (LPS; Sigma–Aldrich, St. Louis, MO, USA) and IFN-g
(R&D System) for further 3 days at 37 C in 5% CO2. Differentiated,
non-activated dendritic cells (monocytes cultured only in
presence of GM-CSF and IL-4) secrete low/none IL-23 and TNFa
whereas secretion of these cytokines is strongly induced upon
activation. Cells were treated with compounds or vehicle (0.1%
DMSO) in duplicates. Treatment was applied either during the
3 days of fully maturation and activation with LPS and IFN-g or
two days after maturation and activation with LPS and IFN-g for
the last 24 h of activation. There was no signiﬁcant difference in
cellular viability under all culture conditions (data not shown).
At termination, supernatants from in vitro cultures were
harvested and assessed for levels of IL-23 (Human IL-23 Quanti-
kine ELISA kit from R&D Systems) and TNF-a (Human ProIn-
ﬂammatory II 4-Plex Assay kit from Meso Scale Diagnostics).
Independent experiments were performed using DCs from four
different donors.
2.6. KC monolayer cultures
Primary human epidermal KCs (Invitrogen Life Technologies,
Carlsbad, CA) were seeded at a concentration of 7.5  104 cells/well
in 12 well plate and cultured at 37 C in 5% CO2 in EpiLife medium
supplemented with 0.2 ng/ml human EGF, 0.2% bovine pituitary
extract (BPE), 5 mg/ml bovine insulin, 5 mg/ml bovine transferrin,0.18 mg/ml hydrocortisone and gentamicin (all from Life Technol-
ogies). The medium was changed the day before and on the day of
treatment (80% conﬂuent cultures) to EpiLife medium without
any supplement. The monolayer cultures were treated in
duplicates and pre-treatment with compounds or vehicle (0.1%
DMSO) was done for 2 h followed by addition of the cytokines IL-
17A (20 ng/ml), IL-22 (20 ng/ml) and TNF-a (5 ng/ml). Upon
stimulation, levels of cytokine secretion were signiﬁcantly induced
compared to untreated controls. After 48 h of treatment, cell
culture supernatants were collected for protein analysis of IL-20
(Human IL-20 Quantikine) and IL-17C (Human IL-17C DuoSet)
using ELISA kits from R&D Systems and of IL-8 and IL-6 using
Human ProInﬂammatory-4 II Ultra-Sensitive Kit from Meso Scale
Diagnostics. Independent experiments were performed using
keratinocytes from three different donors.
2.7. Quantitative real-time RT-PCR (qRT-PCR)
Total RNA was extracted using the RNeasy mini kit (Qiagen,
Germantown, MD) for the T cell cultures and the mirVana kit
(Life Technologies) for the psoriasis skin explants according to
the instructions provided. cDNA synthesis was performed with
the High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA). cDNA was ampliﬁed by quantitative
real-time PCR using Taqman1 Gene Expression Assays (IL4-
Hs00174122_m1, IL8-Hs00174103_m1, IL17A-Hs00174383_m1,
IL22-Hs00220924_m1, IL26-Hs00218189_m1, CXCL1-
Hs00236937_m1, RORC-Hs01076112_m1, GATA3-Hs00231122_m1,
FOXP3-Hs01085834_m1, GAPDH-Hs99999905_m1, PPIA-
Hs99999904_m1, PGK1-Hs99999906_m1, TBP-Hs99999910_m1,
UBC-Hs00824723_m1) using Applied Biosystems ViiATM7 Real-
Time PCR System. Based on experimental data, the three most
stable reference genes that were not affected by calcipotriol or
betamethasone treatment were selected from a panel of potential
reference genes. In the psoriasis skin explants the reference genes
PPIA, GAPDH and PGK1 were used for normalization and in the T cell
cultures the reference genes TBP, PPIA and UBC were used for
normalization.
2.8. Statistical analysis
Values are represented as relative gene expression or percent-
age of the vehicle control (100%) for each experiment. Means and
SEM is calculated from the repeated experiments. By the use of
GraphPad Prism software, statistical analysis is performed with
one-way analysis of variance (ANOVA) followed by Tukey’s
multiple comparison test or with a two-way ANOVA where
written (*P < 0.05; **P < 0.01,***P < 0.001, ****P  0.0001).
3. Results
3.1. Calcipotriol and betamethasone dipropionate additively inhibit
expression of inﬂammatory cytokines in psoriasis skin explant
cultures
Therapeutic intervention with antibodies has underlined the
importance of inhibiting key cytokines, such as IL-17A and TNF-a,
in psoriasis. To elucidate the effects of calcipotriol and betame-
thasone dipropionate, alone and in combination, on psoriasis
inﬂammation, we treated psoriatic skin cultured in an ex vivo
setting that maintains the cellular activities and inﬂammatory
features of psoriatic lesions. Speciﬁcally, we cultured the psoriasis
skin explants in the presence of anti-CD3 and anti-
CD28 antibodies, rhIL-2, and rhIL-23 to stimulate psoriasis-
relevant T cells. qRT-PCR gene expression analysis of the skin
specimens performed 24 h after treatment showed that, compared
Fig. 1. Expression of pro-inﬂammatory cytokines from psoriasis skin is decreased by calcipotriol and betamethasone dipropionate combination treatment.
Cultures of keratome biopsies were treated in triplicates with 100 nM calcipotriol, 1 mM betamethasone (BDP), combination of calcipotriol and betamethasone (100 nM/
1 mM; ratio 1:10 as in the ﬁxed-combination product) or a corresponding vehicle control (0.1% DMSO). (A) IL17A, IL22, IL8 and CXCL1 mRNA expression normalized to PPIA,
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Fig. 2. Treatment with calcipotriol and betamethasone dipropionate affects the activity of DCs resulting in a decreased secretion of TNF-a and IL-23.
Monocytes (CD14+ cells)-derived DCs were cultured in presence of IL-4 and GM-CSF for 5 days and subsequently activated by co-stimulation with LPS and IFN-g for 3 days.
Cells were treated in duplicates with 100 nM calcipotriol, 1 mM betamethasone (BDP), combination of calcipotriol and betamethasone (100 nM/1 mM; ratio 1:10 as in the
ﬁxed-combination product) or a corresponding vehicle control (0.1% DMSO). Treatment was applied after the ﬁrst 5 days in culture and before and throughout the 3 days of
activation with LPS and IFN-g (A) or two days after activation with LPS and IFN-g and throughout the last 24 h of activation (B). Protein levels of IL-23 and TNF-a were assessed
by ELISA and MSD, respectively at the end of the 3 days of activation with LPS and IFN-g. The results expressed as the percentage difference compared to vehicle treatment
control are mean values  SEM from independent experiments using monocytes (CD14+ cells)-derived DCs from peripheral blood of four different healthy volunteers (n = 4).
One-way ANOVA followed by Tukey’s multiple comparison tests were used to compare treatment effect. ****P  0.0001; ***P  0.001; **P  0.01; *P  0.05.
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and betamethasone signiﬁcantly inhibited the mRNA expression of
IL17A and IL22 by skin resident immune cells, as well as theGAPDH and PGK1 reference genes after 24 h of treatment. The relative gene expression va
skin samples from six different donors (n = 6). (B) Protein level of IL-17A, IL-8, TNF-a and
treatment. The results expressed as the percentage difference compared to vehicle tre
samples from ﬁve different donors (n = 5). A two-way ANOVA statistical test was used expression of the IL-17-induced chemokines IL8 and CXCL1
(Fig. 1A). The reduction of IL17A and IL22 expression by the
combination treatment was more pronounced than the effect oflues  upper and lower limits are mean values from independent experiments using
 IL-10 and that of IL-22 were measured by MSD and ELISA, respectively after 72 h of
atment control are mean values  SEM from independent experiments using skin
to compare treatment effect. ****P  0.0001; ***P  0.001; **P  0.01; *P  0.05.
Fig. 3. Effect of calcipotriol and betamethasone dipropionate on the differentiation of Th1/Th17 and Tc1/Tc17 cells.
Anti-CD3/anti-CD28-stimulated CD4+ T cells and CD8+ T cells from peripheral blood of healthy volunteers were cultured in presence of Th/Tc1 and Th/Tc17 polarizing factors
for 7 days. Cells were treated in duplicates with 100 nM calcipotriol, 1 mM betamethasone (BDP), combination of calcipotriol and betamethasone (100 nM/1 mM; ratio 1:10 as
in the ﬁxed-combination product) or a corresponding vehicle control (0.1% DMSO). Treatment was applied at the beginning and throughout the 7 days of in vitro cultures. (A)
RORC, GATA3 and FOXP3 mRNA expression normalized to TBP, PPIA and UBC. The relative gene expression values  upper and lower limits are mean values from independent
experiments using CD4+ T cells from peripheral blood of six different healthy volunteers (n = 6). The level of IL-17A, IL-4, IL-8, IL-10 and TNF-a and of IL-22 secreted by CD4+ T
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more recently described Th17-associated cytokine IL-26 was also
detected in the samples. However, none of the treatments affected
IL26 expression (data not shown).
We also investigated cytokine protein levels in supernatants
from the 72-hour ex vivo cultures (Fig.1B). Compared to the vehicle
control, treatment with combination of calcipotriol and betame-
thasone signiﬁcantly inhibited the production of IL-17A, IL-22,
TNF-a and IL-8 (38%, 64%, 57% and 21% inhibition of vehicle
control, respectively), while mono-treatment with betamethasone
showed less effect, as seen in the gene expression analysis. Mono-
treatment with calcipotriol slightly inhibited the production of IL-
17A (15% inhibition of vehicle control) and signiﬁcantly increased
the production of IL-10 (65% increase).
Of note, the ﬁndings from this study both on gene expression
and protein levels clearly indicated that the combination of
calcipotriol and betamethasone resulted in a signiﬁcantly stronger
effect compared to betamethasone mono-treatment. This suggests
that calcipotriol adds signiﬁcantly to the anti-psoriatic effect of
betamethasone when the two agents are used in combination.
3.2. Decreased TNF-a and IL-23 levels in activated DCs after treatment
with calcipotriol and betamethasone
The complex interplay between DCs, T cells and KCs is pivotal
during psoriatic inﬂammation. Inﬂammatory DCs produce TNF-a
and are the major producer of IL-23, an essential cytokine for the
expansion and maturation of Th17 cells. Therefore, we investi-
gated whether calcipotriol and betamethasone affected the
release of TNF-a and IL-23 by human DCs derived from CD14+
monocytes upon maturation with IL-4 and GM-CSF and activa-
tion with LPS and IFN-g (Fig. 2). Treatment with calcipotriol,
betamethasone or the combination prior to activation of DCs
with LPS and IFN-g, signiﬁcantly inhibited the secretion of IL-23,
compared to the vehicle control (% suppression: 78%, 55% and
90% compared to vehicle, respectively; P < 0.0001) (Fig. 2A, left
panel). Treatment with calcipotriol alone or the combination, but
not treatment with betamethasone alone, signiﬁcantly inhibited
the secretion of TNF-a (% suppression: 49% and 55% compared to
vehicle, respectively; P < 0.0001) (Fig. 2A, right panel). Impor-
tantly, the inhibition of both IL-23 and TNF-a secretion was found
to be mostly driven by calcipotriol and thus the effect by the
combination of calcipotriol and betamethasone was signiﬁcantly
better than by betamethasone alone. However, when DCs were
treated with calcipotriol, betamethasone or the combination after
activation with LPS and IFN-g, calcipotriol alone slightly inhibited
the secretion of IL-23 (% suppression: 33% inhibition of vehicle
control; P < 0.05), while betamethasone alone and in combination
with calcipotriol signiﬁcantly inhibited the production of IL-
23 compared to the vehicle control (% suppression: 74% and 80%
inhibition of vehicle control, respectively; P < 0.0001) (Fig. 2B, left
panel). Betamethasone alone or in combination with calcipotriol
also reduced the secretion of TNF-a, although not signiﬁcantly (%
suppression: 45% and 35% inhibition, respectively), whereas
calcipotriol did not affect TNF-a release by activated DCs
(Fig. 2B, right panel).
Therefore, treatment with the combination of calcipotriol and
betamethasone has a therapeutically beneﬁcial effect with
respect to the suppression of both IL-23 and TNF-a production
from DCs.cells (B) and CD8+ T cells (C) were measured by MSD and ELISA, respectively. The results
mean values  SEM from independent experiements using CD4+ and CD8+ T cells from pe
One-way ANOVA followed by Tukey’s multiple comparison tests were used to compar3.3. Effect of calcipotriol and betamethasone dipropionate on the
differentiation of Th1/Th17 and Tc1/Tc17 cells
Psoriasis is primarily regarded as a T cell-mediated inﬂamma-
tory disease with presence of CD8+ T cells in the epidermis and
CD4+ T cells mostly in the dermis. Both T cell populations are found
to be polarised towards type 1 and type 17 immune phenotypes
(Th1 and Th17 cells and Tc1 and Tc17) and to play an essential role
in the initiation and perpetuation of psoriatic skin inﬂammation.
Therefore, we examined the effect of calcipotriol and betame-
thasone on the differentiation processes to Th/Tc1 and Th/
Tc17 cells, by analysing the expression of transcription factors
and cytokines that are phenotypically associated with different T
cell subsets. To address this aim, treatment with calcipotriol,
betamethasone or the combination was added at the beginning
and throughout the whole period of in vitro culture (Fig. 3). We ﬁrst
performed gene expression analysis of CD4+ T cells for the
transcription factors RORgt, GATA3 and FOXP3 related to Th/
Tc17, Th/Tc2 and Treg cells, respectively (Fig. 3A). Compared to the
vehicle control, all treatments signiﬁcantly inhibited RORC
expression (P < 0.001). Interestingly, the effect of calcipotriol
alone or in combination with betamethasone was found to be
signiﬁcantly better (P < 0.01 and P < 0.001) than betamethasone
alone (Fig. 3A, left panel), suggesting that calcipotriol has a major
role in regulating RORC expression. Furthermore, IL17A and IL26
gene expression was also analysed and found to mirror the RORC
expression (data not shown), supporting the dominating effect by
calcipotriol. Of note, treatment with calcipotriol alone or in
combination with betamethasone, but not treatment with
betamethasone alone, increased both GATA3 and FOXP3 gene
expression; GATA3 expression was signiﬁcantly higher (P < 0.05)
after calcipotriol mono-treatment compared to vehicle (Fig. 3A,
middle and right panel). When IL4 gene expression was examined,
it was found to parallel GATA3 expression (data not shown),
supporting the overall ﬁndings.
Next, we investigated the effect of calcipotriol and betametha-
sone on cytokines secreted by CD4+ and CD8+ Tcells (Fig. 3B and 3C,
respectively). Compared to the vehicle controls, all treatments
signiﬁcantly inhibited the production of the Th17-related cyto-
kines, IL-17A and IL-22, the Th1-related cytokine IFN-g (data not
shown) as well as the production of the pro-inﬂammatory
cytokines IL-8 and TNF-a (Fig. 3B). In contrast, compared to the
vehicle control, mono-treatment with calcipotriol signiﬁcantly
increased the secretion of Th2-associated cytokines, including IL-4
(P < 0.001), IL-5 (P < 0.001), IL-13 (P < 0.001) (Fig. 3B and data not
shown) and the secretion of Treg-associated cytokine IL-10
(P < 0.001) (Fig. 3B). Mono-treatment with betamethasone signiﬁ-
cantly decreased the secretion of Th2- and Treg-associated
cytokines, conﬁrming its broad immunosuppressive effect. Inter-
estingly, it was found that treatment with the combination of
calcipotriol and betamethasone also increased the secretion of
Th2- and Treg-associated cytokines, although to a lesser degree
compared to treatment with calcipotriol alone, suggesting that the
presence of calcipotriol counteracts the inhibition of Th2-related
cytokines by betamethasone. In line with the gene expression
analysis and with the results from the psoriasis skin explant
cultures, treatment with the combination of calcipotriol and
betamethasone was found to be signiﬁcantly more effective than
betamethasone alone (Fig. 3B, signiﬁcant differences are shown in
the graphs), suggesting a meaningful contribution by calcipotriol
to the anti-inﬂammatory effect of betamethasone when the two expressed as the percentage difference compared to vehicle treatment control are
ripheral blood of six (n = 6) and four different healthy volunteers (n = 4), respectively.
e treatment effect. ****P  0.0001; ***P  0.001; **P  0.01; *P  0.05.
Fig. 4. Effect of calcipotriol and betamethasone dipropionate on the activity of Th1/Th17 and Tc1/Tc17 cells.
Anti-CD3/anti-CD28-stimulated CD4+ T cells and CD8+ T cells from peripheral blood of healthy volunteers were cultured in presence of Th/Tc1 and Th/Tc17 polarizing factors
for 7 days. Cells were treated in duplicates with 100 nM calcipotriol, 1 mM betamethasone (BDP), combination of calcipotriol and betamethasone (100 nM/1 mM; ratio 1:10 as
in the ﬁxed-combination product) or a corresponding vehicle control (0.1% DMSO). Treatment was applied for 24 h after 6 days of in vitro differentiation. (A) RORC, GATA3 and
FOXP3 mRNA expression normalized to TBP, PPIA and UBC. The relative gene expression values  upper and lower limits are mean values from independent experiments using
CD4+ T cells from peripheral blood of six different healthy volunteers (n = 6). The level of IL-17A, IL-4, IL-8, IL-10 and TNF-a and of IL-22 secreted by CD4+ T cells (B) and CD8+ T
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inhibiting the expression of pro-inﬂammatory cytokines associat-
ed with the Th1/Th17 phenotype, treatment with calcipotriol alone
or in combination with betamethasone signiﬁcantly increased the
production of Th2- and Treg-associated cytokines, indicating that
the differentiation/maturation process to Th1/Th17 is skewed
towards a more Th2/Treg phenotype.
Similar results were found when investigating the effect of
calcipotriol and betamethasone on cytokines secreted byCD8+Tcells
(Fig. 3C). However, the effect by mono-treatments with calcipotriol
or betamethasone on IL-10 and TNF-a productionby CD8+Tcells was
found to be lower than the effects seen in CD4+ T cells.
3.4. Effect of calcipotriol and betamethasone dipropionate on the
activity of Th1/Th17 and Tc1/Tc17 cells
Because the majority of pathogenic T cells found in psoriasis
plaques display a typical phenotype of activated memory T cells, we
also investigated the effect of calcipotriol and betamethasone on the
activity of differentiated Th/Tc1 and Th/Tc17 cells, by analysing the
expression of transcription factors and cytokines that are phenotyp-
ically associated with different Tcell subsets. Treatment was applied
for 24 h after 6 days of in vitro differentiation (Fig. 4). Contrary to the
treatment effect on the differentiation processes, none of the
treatments affected the expression of RORC, GATA3 or FOXP3
(Fig. 4A) or that of IL4 or IL17A (data not shown) in CD4+ T cells,
although treatment with betamethasone alone or in combination
showed a tendency to inhibit the RORC and IL17A expression (Fig. 4A,
left panel and data not shown). However, treatment with
calcipotriol alone or in combination with betamethasone, but not
treatment with betamethasone alone, signiﬁcantly inhibited IL26
gene expression compared to the vehicle control, and the effect of
the combination was found to be signiﬁcantly stronger than
betamethasone mono-treatment (data not shown).
The effects of calcipotriol, betamethasone or the combination
on the production of cytokines by differentiated T cells were
examined in culture supernatants. In comparison with the vehicle
control, all treatments markedly inhibited IL-17A and IL-22 secre-
tion both by Th17 cells (Fig. 4B) and by Tc17 cells (Fig. 4C). The
combination of calcipotriol and betamethasone, but not the mono-
treatments, signiﬁcantly inhibited IFN-g secretion by Th1 cells
only (data not shown). Moreover, secretion of TNF-a by Th1/
Th17 and Tc1/Tc17 cells was signiﬁcantly inhibited by betametha-
sone mono-treatment and in combination with calcipotriol, but
not by calcipotriol mono-treatment (Fig. 4A and 4B). On the
contrary, none of the treatments affected the secretion of IL-8 by Th
cells (Fig. 4B), while calcipotriol mono-treatment and in combina-
tion with betamethasone, but not betamethasone mono-treat-
ment, signiﬁcantly inhibited the secretion of IL-8 by Tc cells
(Fig. 4C).
Contrary to the treatment effect observed on the differentiation
processes, none of the treatments signiﬁcantly affected the
secretion of the type 2 cytokines, IL-4 and IL-13 or that of the
regulatory cytokine IL-10, which is in line with the data from the
gene expression (Fig. 4A and data not shown).
3.5. Treatment with calcipotriol and betamethasone impairs secretion
of pro-inﬂammatory cytokines by human KCs
Mediators released by activated skin resident T cells stimulate
activation and proliferation of KCs, which, in turn, secretecells (C) were measured by MSD and ELISA, respectively. The results expressed as the pe
from independent experiments using CD4+ and CD8+ T cells from peripheral blood of six
followed by Tukey’s multiple comparison tests were used to compare treatment effectautocrine and paracrine factors maintaining their inﬂammatory
and hyper-proliferating state and promoting recruitment and
activation of immune cells.
Therefore, we investigated the effect of calcipotriol and
betamethasone on the pro-inﬂammatory mediators IL-17C, IL-
20, IL-6 and IL-8 released from KCs upon stimulation with
Th17 cell-related cytokines (IL-17A, IL-22 and TNF-a), thus
mimicking the cytokine environment in psoriatic skin (Fig. 5).
The secretion of all tested cytokines was signiﬁcantly inhibited by
all treatments compared to the vehicle control. Upon treatment
with calcipotriol, betamethasone, or the combination, IL-17C and
IL-20 secretion was found to be inhibited by 75%, 56% and 86% and
by 82%, 60% and 90%, respectively (P < 0.0001 compared to vehicle)
(Fig. 5, upper panel). Importantly, the inhibition of both IL-17C and
IL-20 was mostly affected by calcipotriol alone or in combination
with betamethasone, and treatment with the combination of
calcipotriol and betamethasone resulted in a signiﬁcantly better
effect compared to betamethasone alone. IL-6 secretion was
inhibited by 62%, 38% and 73% of the vehicle control with
calcipotriol, betamethasone or the combination, respectively
(P < 0.0001 compared to vehicle) (Fig. 5, lower panel). Treatment
with calcipotriol or betamethasone alone inhibited the secretion of
IL-8 by 44% of the vehicle control, while the combination inhibited
the secretion of IL-8 more profoundly (64% inhibition) (Fig. 5,
lower panel). In summary, these data suggest an additive anti-
inﬂammatory effect in KCs by the two agents in combination in line
with the ﬁndings from the DC and T cell cultures and the psoriasis
explants.
4. Discussion
In lesional psoriatic skin, the inﬂammatory process is main-
tained via the interaction of DCs and T cells with KCs through the
secretion of key soluble mediators, such as TNF-a, IL-23 and IL-17
[3]. Topical treatment of psoriasis vulgaris with a combination of
calcipotriol and betamethasone leads to higher efﬁcacy than either
monotherapy alone [22–29]. Because antibody-based treatments
neutralising TNF-a, IL-17A and IL-23 are remarkably effective for
the treatment of psoriasis, we investigated whether inhibition of
TNF-a and the IL-23/Th17 immune axis contributes to the efﬁcacy
of the calcipotriol and betamethasone combination treatment.
The present study using psoriasis skin explants showed that IL-
17A, IL-22, TNF-a and IL-8 were reduced signiﬁcantly more by the
combination rather than by mono-treatment. These ﬁndings are in
line with the clinical efﬁcacy of the combination therapy. Of note,
we also found that the treatment with calcipotriol alone induced
IL-10 secretion in psoriasis skin cultures, in agreement with
previously reported regulatory responses mediated by VDR
agonists [16,30]. Using cultured peripheral blood cells from
rheumatoid arthritis patients, vitamin D (1,25(OH) 2D3) and
dexamethasone exerted additive effects in reducing Th1 and
Th17 cytokines [18]. Although our ﬁndings are consistent with this
study, we used psoriasis skin with active inﬂammation rather than
peripheral blood T cells from psoriasis patients, as a recent study
has shown low or no systemic activation of Tcm and Tem subsets in
psoriasis patients [31].
In addition, our in vitro cell culture systems recapitulating key
cellular activities of psoriasis inﬂammation further demonstrated
the superior inhibitory effect of the combination of calcipotriol and
betamethasone compared to mono-treatment. The combination
treatment reduced TNF-a and IL-23 production by in vitrorcentage difference compared to vehicle treatment control are mean values  SEM
 (n = 6) and four different healthy volunteers (n = 4), respectively. One-way ANOVA
. ****P  0.0001; ***P  0.001; **P  0.01; *P  0.05.
Fig. 5. Treatment with calcipotriol and betamethasone dipropionate impairs secretion of pro-inﬂammatory cytokines by human KCs.
Human KC monolayer cultures were treated with calcipotriol (100 nM), betamethasone (1 mM), calcipotriol in combination with betamethasone (100 nM/1 mM; ratio 1:10)
followed by stimulation with the mix of IL-17A, IL-22 and TNF-a for 48 h. The levels of IL-17C, IL-20 and of IL-8 and IL-6 were measured by ELISA and MSD, respectively. The
results expressed as the percentage difference compared to vehicle treatment control are mean values  SEM from independent experiments using human primary KCs from
three (n = 3) different donors. One-way ANOVA followed by Tukey’s multiple comparison tests were used to compare treatment effect. ****P  0.0001; ***P  0.001; **P  0.01.
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Furthermore, calcipotriol profoundly affected the differentiation
process of inﬂammatory DCs, resulting in pronounced inhibition of
TNF-a and IL-23 production. However, we cannot negate the
possibility that this effect could be due to the induction of a
tolerogenic state in DCs by VDR agonists [12–14], rather than by a
direct effect of calcipotriol on the transcription of TNF-a and IL-23.
In contrast, betamethasone mainly showed the inhibitory effect on
activated inﬂammatory DCs, suggesting a shift in the responsive-
ness to VDR and glucocorticoid receptor agonists during matura-
tion and activation of inﬂammatory DCs.
Several studies have reported that VDR and glucocorticoid
receptor agonists impair the differentiation of Th1 and Th17 cells
and promote regulatory T cell functions and Th2 differentiation
[17,18,30,32,33]. Our ﬁndings on the effect on Th1/Th17 cell
differentiation by the combination are in complete agreement with
these published data as shown by the remarkable decrease of TNF-
a, IL-17A, IL-22 and IFN-g secretion with concomitant increased
production of the regulatory cytokine IL-10 and the type
2 cytokines IL-4, IL-5 and IL-13 by CD4+ T cells. The profound
effect of calcipotriol on T cell differentiation is also supported by
the decreased expression of the RORgt transcription factor and
increased expression of FOXP3 and GATA3. Surprisingly, the
combination treatment leads to increased GATA3 andFOXP3 gene expression similarly to the levels induced by
calcipotriol alone, indicating that calcipotriol reverses the inhibi-
tory effect of betamethasone. However, the effect of calcipotriol on
IL-4 and IL-10 production was weakened when combined with
betamethasone. The immune modulatory effect of calcipotriol via
induction of IL-10 and FOXP3+ Treg cells is thought to be clinically
important for disease resolution.
Despite the fact that differentiated Tem cells contribute to the
initiation and persistence of chronic inﬂammation and thus could
be targeted by therapeutic agents, there are no studies investigat-
ing the effect of glucocorticoids and VDR agonists on fully
differentiated Th1/Th17 cells. Here, we demonstrated that
calcipotriol potentiates the inhibitory effects of betamethasone
on RORgt expression and on the production of TNF-a, IL-17A, IL-
22 and IFN-g by in vitro differentiated Th1/Th17 cells. Interestingly,
while calcipotriol plays a major role in impairing Th1/
Th17 differentiation, betamethasone primarily reduces the activity
of differentiated Th1/Th17. However, compared to the effect of
treatment during T cell differentiation, both calcipotriol and
betamethasone were less effective when administered to already
differentiated cells. The combination also impaired the differenti-
ation and activity of CD8+ T cells in a similar way to CD4+ T cells.
Importantly, the complementary mode-of-action of calcipotriol
and betamethasone on the T cell differentiation process and on T
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relevance. Activated Tem cells and inﬂammatory DCs found in
lesional psoriatic skin will be affected by the combination
treatment and thus downregulate their inﬂammatory activity.
On the contrary, Tem cells and inﬂammatory DCs in a resting state,
which are present in the periphery of the lesion or in neighbouring
non-involved skin, may be induced to differentiate into regulatory
cells by the combination treatment. This may lead to improvement
of the response rate and to tolerance induction in the skin that
could decrease the development of new lesions and hence
maintain longer disease remission.
In psoriasis, KCs are the target of inﬂammatory cytokines,
including IL-17A. In response to cytokines, KCs produce a host of
soluble mediators that in turn fuel the inﬂammatory processes by
maintaining T cell activation as well as their own hyper-
proliferative and inﬂammatory status. Among various KC-released
soluble mediators, IL-6 is involved in the growth and differentia-
tion of dermal and epidermal cells and is a key factor driving
Th17 differentiation, whereas IL-8 is a potent neutrophil chemo-
attractant in psoriatic skin. IL-17C exerts autocrine effects on KCs
with a functional similarity to IL-17A, and paracrine effects on
Th17 cells, thereby potentially further amplifying the inﬂammato-
ry function of Th17 cells. IL-20, similarly to IL-22, induces KC
proliferation and alters keratinocyte differentiation, leading to
epidermal hyperplasia. We showed that calcipotriol alone and in
combination with betamethasone effectively inhibits the produc-
tion of IL-6, IL-8, IL-17C and IL-20 from human KCs, thereby
conﬁrming the inhibitory effect of vitamin D on KC activities [19].
Betamethasone alone was also found to inhibit the secretion of the
cytokines examined, as expected by its immunosuppressive
activity, but with a signiﬁcant inferior capability than in
combination with calcipotriol.
In conclusion, we presented the ﬁrst mode-of-action study for
calcipotriol and betamethasone combination treatment, revealing
a unique and supplementary immune modulatory effect on TNF-a
and the IL-23/Th17 immune axis that are keenly associated with
psoriasis inﬂammation. Overall, the results support the superior
clinical efﬁcacy of the combination product compared to the
respective mono-treatments in psoriasis patients.
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